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The unpredictable nature of bioterrorism and the absence of real-time detection systems have highlighted
the need for an efficient postexposure therapy for Bacillus anthracis infection. One approach is passive
immunization through the administration of antibodies that mitigate the biological action of anthrax toxin. We
isolated and characterized two protective fully human monoclonal antibodies with specificity for protective
antigen (PA) and lethal factor (LF). These antibodies, designated IQNPA (anti-PA) and IQNLF (anti-LF),
were developed as hybridomas from individuals immunized with licensed anthrax vaccine. The effective
concentration of IQNPA that neutralized 50% of the toxin in anthrax toxin neutralization assays was 0.3 nM,
while 0.1 nM IQNLF neutralized the same amount of toxin. When combined, the antibodies had additive
neutralization efficacy. IQNPA binds to domain IV of PA containing the host cell receptor binding site, while
IQNLF recognizes domain I containing the PA binding region in LF. A single 180-g dose of either antibody
given to A/J mice 2.5 h before challenge conferred 100% protection against a lethal intraperitoneal spore
challenge with 24 50% lethal doses [LD50s] of B. anthracis Sterne and against rechallenge on day 20 with a more
aggressive challenge dose of 41 LD50s. Mice treated with either antibody and infected with B. anthracis Sterne
developed detectable murine anti-PA and anti-LF immunoglobulin G antibody responses by day 17 that were
dependent on which antibody the mice had received. Based on these results, IQNPA and IQNLF act indepen-
dently during prophylactic anthrax treatment and do not interfere with the establishment of endogenous
immunity.
Bacillus anthracis, the causative agent of anthrax, is a spore-
forming, gram-positive bacterium. Following inhalation, spores
are phagocytosed by alveolar macrophages and transported
through the lymphatic channels to hilar and tracheobronchial
lymph nodes, where the spores germinate, leading to the mul-
tiplication and systemic circulation of vegetative bacilli (13,
43). Critical to the virulence of B. anthracis is the secretion of
a tripartite exotoxin consisting of two enzymatically active sub-
units: lethal factor (LF) and edema factor (EF). These proteins
bind to protective antigen (PA), the cell-binding component,
to form lethal toxin (LeTx) and edema toxin, respectively (53).
The biological activities of LeTx and edema toxin are anal-
ogous to those of other A-B toxin systems (14). PA initially
binds to a cell surface receptor, including human capillary
morphogenesis protein 2 and tumor endothelial marker 8 (4,
45), and undergoes furin-like mediated cleavage of the N-
terminal domain. This event yields an amino-terminal 20-kDa
fragment and a carboxyl-terminal 63-kDa activated PA63 pro-
tein with exposed LF/EF binding domains. The PA63 con-
former assembles to form a ring-shaped heptamer with the
capacity to bind up to three copies of LF or EF (22, 31, 32). At
this point the toxin complex is endocytosed. Subsequent acid-
ification of the endosome causes the PA63 heptamer to insert
into the membrane, forming a transmembrane channel that
traffics LF and EF to the cytosol (29). LF endopeptidase ac-
tivity with the MEK family of signal transduction proteins
down-regulates both the innate and acquired immune re-
sponses by inhibiting cytokine responses, dendritic cell re-
sponses, and B- and T-cell immunity (1, 30). EF, an adenylate
cyclase, incapacitates phagocytes and cytokine pathways
through cyclic AMP induction and up-regulates the PA63 re-
ceptor on target cells (17, 36). Given the central role of the
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toxins in anthrax pathology, the ability to neutralize their ef-
fects is of value at all stages of infection.
The credentials of B. anthracis as an aerosolized bioterror
agent were confirmed by the 2001 postal attacks in the United
States, which resulted in five deaths (20). These events under-
scored the need for postexposure medical countermeasures
that are effective, particularly during middle to advanced
stages of infection, when bacteremia and toxemia ensue. Ani-
mal studies have previously suggested that early treatment of
anthrax is essential since the disease reaches a point when
antibiotics are no longer effective due to the accumulation of a
lethal level of toxin (48, 49, 56). In order to counteract the
limitations of antibiotics, several groups have been pursuing
various therapeutic strategies that evoke rapid protection
against anthrax by targeting PA, LF, or capsular antigen (7, 18,
21, 23, 28, 33, 35, 37, 46, 59, 63).
The most promising approach has been administration of
antitoxin antibodies to generate a state of immediate passive
immunity. This therapy involves the transfer of serum from an
immunized donor or monoclonal antibodies (MAbs) to an
exposed or at risk recipient. The efficacy of this treatment has
been demonstrated in an anthrax guinea pig challenge model
using polyclonal anti-PA serum from immunized guinea pigs
(26). A murine MAb specific for LF has also exhibited protec-
tive efficacy during experimental LeTx challenge of athymic
nude mice (63). One of the major concerns with this therapeu-
tic agent is the immunogenicity of the antibody as a foreign
protein. This concern has been partially circumvented by the
generation of an affinity-enhanced, humanized, anti-PA MAb
that was developed from a murine immunoglobulin G (IgG)
(33). More recently, human peripheral blood lymphocytes
from immunized humans have been used in hybridomas as
progenitors of prophylactic anti-PA antibodies (44, 58). The
use of human IgG eliminates the risk of adverse reactions
associated with nonhuman serum and antibodies while the
immune system recall response is utilized to produce high-
affinity toxin-neutralizing antibodies.
Here we report the isolation and characterization of two
protective PA- and LF-specific MAbs obtained from human
donors. This is the first reported example of a protective hu-
man-derived LF MAb. Each antibody was tested for its indi-
vidual capacity to neutralize LeTx activity in vitro. The anti-
bodies were also assayed together in various combinations to
assess the additive neutralizing potential. The efficacy of the
anti-PA and anti-LF MAbs as a prechallenge treatment for
mice infected intraperitoneally (i.p.) with a lethal dose of B.
anthracis Sterne spores was evaluated. We also examined the
ability of the protected mice to survive a second lethal chal-
lenge 20 days after the initial infection. Endogenous murine
anti-PA and anti-LF IgG responses were measured, and their
protective efficacy was determined.
MATERIALS AND METHODS
Ethics. Human blood samples were obtained with appropriate ethical permis-
sion (IQ Therapeutics BV, The Netherlands). The experiments reported here
were conducted in compliance with the Animal Welfare Act and in accordance
with the principles set forth in the Guide for the Care and Use of Laboratory
Animals (19).
Development and identification of the anti-PA and anti-LF hybridomas. Blood
samples were drawn from healthy individuals immunized with the United King-
dom-licensed anthrax vaccine following annual booster immunizations. Samples
demonstrating anthrax LeTx-neutralizing activity in cytotoxicity assays (15, 40)
were selected for hybridoma development using a polyethylene glycol-based
variant of the hybridoma electrofusion technology described by H. Groen and
H. H. Westra (U.S. patent applications USSN 60/710,626 and USSN 11/072,102).
Hybridoma fusions were screened for expression of anti-PA- and anti-LF-specific
antibodies by enzyme-linked immunosorbent assays (ELISAs) (2). Hybridoma
clones producing anti-PA and anti-LF MAb IgG were expanded and stabilized,
and the antibodies were evaluated for anthrax LeTx neutralization (18). Candi-
date anti-PA and anti-LF antibodies were isotyped using a human Ig subclass
ELISA kit (Invitrogen, Carlsbad, CA).
Anthrax LeTx neutralization activity assay. The capacity of the candidate
anti-PA and anti-LF MAbs to neutralize LeTx was measured by the toxin neu-
tralization activity (TNA) assay, which has been described in detail elsewhere
(41, 54). Prior to testing, recombinant PA (rPA) and recombinant LF (rLF) were
titrated for toxin potency with J774A.1 cells (TIB-67; American Type Culture
Collection, Manassas, VA). The protein concentrations of rPA and rLF that
resulted in more than 95% cell lysis at a fixed cell density of 3  104 cells/well in
this assay were 50 and 24 ng/ml, respectively. Antibodies were assayed individ-
ually and in combination at various ratios to determine their individual and
combined neutralization capacities. Test antibodies for individual analysis were
prepared in a separate 96-well microtiter plate as twofold dilutions in triplicate.
Combination assays were conducted in triplicate with two sets of MAbs. The first
set of samples was prepared with a fixed concentration of anti-PA (30.6 ng/ml;
144 pM) mixed with anti-LF at concentrations of 9, 18, and 36 ng/ml. The second
set of samples was prepared with a fixed concentration of anti-LF (9 ng/ml; 60
pM) mixed with anti-PA at concentrations of 21.6, 43.3, and 86.3 ng/ml.
Assay endpoints were calculated using SAS statistical analysis software, ver-
sion 9.0 (SAS Institute Inc., Cary, NC), running an endpoint calculation algo-
rithm developed at the CDC (54). The primary endpoint calculated from the
four-parameter logistic log fit curve is the 50% effective antibody dilution
(ED50). This value is the reciprocal of the antibody dilution corresponding to
the inflection point (“c” parameter) of the four-parameter logistic log fit of the
serum neutralization curve (antibody dilution factor versus optical density). The
final endpoint value used in the present study is the effective molar concentration
required for 50% toxin neutralization (EC50), which was calculated from the
ED50 using a nominal molecular mass of 150 kDa for human IgG.
Domain mapping of PA- and LF-specific MAbs. Two different approaches
were utilized to map the specific antigen domains recognized by the candidate
anti-PA and anti-LF antibodies. The target domain recognized by the anti-PA
MAb was identified using glutathione S-transferase (GST) fusions of the four PA
domains in modified ELISAs. The development of these fusions has been de-
scribed previously (10). Equimolar concentrations (6.02  1011 mol/ml, equiv-
alent to 5 g/ml of rPA) of the GST fusions and rPA were used in ELISAs, where
the assay cutoff was defined as the dilution resulting in an optical density at 414
nm that was 0.1 U above the nonspecific background (61). The candidate anti-PA
antibody was assayed in duplicate using a starting dilution of 1:100. The results
of this assay were confirmed in native and denaturing Western blots (55) with
rPA and PA domain IV resolved on a 4 to 20% Tris-HCl Ready Gel (Bio-Rad,
Hercules, CA).
Domain mapping of the LF-specific MAb was accomplished with rLF domains
purified by cobalt affinity chromatograph. LF domains I (amino acids 1 to 262),
II (amino acids 263 to 552), III (amino acids 303 to 385), IV (amino acids 552 to
776), and II to IV (amino acids 263 to 776) (6) were PCR amplified and cloned
downstream of and in frame with the T5 promoter and seven-His tag sequence
of the Escherichia coli expression vector pQE30 (QIAGEN, Valencia, CA).
Constructs were confirmed via dideoxy sequencing. Domains were expressed
from either E. coli XL-1Blue or E. coli M15. Host strains were grown in LB
medium (BD-Difco, Franklin Lakes, NJ) with the appropriate antibiotics to an
optical density at 600 nm of 0.55 to 0.65 and induced with 1 mM isopropyl--D-
thiogalactoside (IPTG) (Sigma Fine Chemicals, St. Louis, MO) for 4 to 24 h at
25 to 37°C. Cells were pelleted, washed, and lysed with a French press at 16,000
lb/in2. The resulting lysates were cleared by centrifugation at 45,000  g for 15
min. A cleared lysate was batch bound to TALON resin (Clontech, Mountain
View, CA) and then washed with 10 column volumes of 300 mM NaCl, 50 mM
Na2HPO4, 20 mM imidazole (pH 7.0). Proteins were eluted in 5 column volumes
of 300 mM NaCl, 50 mM Na2HPO4, 150 mM imidazole (pH 7.0). Fractions
containing a protein of the correct size (determined by sodium dodecyl sulfate
[SDS]-polyacrylamide gel electrophoresis with Coomassie blue staining) were
pooled and dialyzed into 10 mM HEPES, 50 mM NaCl (pH 7.5). Recognition of
the target domain by the candidate anti-LF MAb was determined by native and
denaturing Western blotting (55) using rLF and the domains resolved using 50
ng/lane on a 4 to 20% Tris-HCl Criterion precast gel (Bio-Rad). The proteins
were also resolved on a 4 to 12% bis-Tris Criterion XT precast gel (Bio-Rad) and
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silver stained using an Invitrogen SilverQuest kit according to the manufacturer’s
instructions.
Mouse passive protection studies. B. anthracis Sterne (34F2) spores were
prepared in sporulation broth (containing [per liter] 23 g of nutrient broth, 0.025
g of MnSO4  H2O, and 0.25 g of KH2PO4). After a 72-h incubation at 37°C,
spores were harvested by centrifugation, washed with phosphate-buffered saline
(PBS), and enumerated by viable plate counting. Immediately prior to challenge
the spores were diluted to obtain the appropriate concentration in endotoxin-
free PBS and administered to the mice by i.p. injection. The 50% lethal dose
(LD50) of this strain in A/J mice is 2  104 spores (Helen Flick-Smith, unpub-
lished results). The A/J mouse model was selected for this study because it is an
established model for i.p. challenge (3, 39) and A/J mice are sensitive to the B.
anthracis strain used in this investigation (39, 60).
Groups of 10 6- to 8-week-old female A/J mice (The Jackson Laboratory, Bar
Harbor, ME) were inoculated i.p. with 180 g of either the anti-PA or anti-LF
antibody in 100 l of sterile endotoxin-free PBS (Invitrogen-Gibco, Carlsbad,
CA). After 2.5 h the mice were challenged i.p. with an average of 4.8  105 CFU
per mouse (approximately 24 LD50s). Surviving mice were rechallenged i.p. 20
days later with the same stock of spores at a level of 8.3  105 CFU per mouse
(approximately 41 LD50s). The infection dose was increased in this challenge to
determine if immunity to the anthrax toxins could develop in the presence of the
toxin-specific antibodies. Both challenges included a control group of five mice
that were inoculated i.p. with 100 l of sterile endotoxin-free PBS prior to
challenge. Following challenge, mice were monitored four times daily for evi-
dence of morbidity or mortality during the first week and twice daily thereafter.
Blood samples were collected from healthy mice via tail bleeding using capillary
microvette tubes (Sarstedt, Germany) on days 4 (pretreatment and prechal-
lenge), 10, 17, 27 (after the second challenge), and 34 (terminal bleed). Symp-
tomatic mice were euthanized with CO2 prior to blood and tissue collection.
Hearts were collected postmortem from all mice, swabbed onto 5% (vol/vol)
sheep blood agar, and incubated at 37°C for 24 to 72 h.
Analysis of endogenous mouse IgG responses. Murine anti-PA, anti-LF, and
anti-human MAb IgG concentrations were quantified by ELISAs. Briefly, Im-
mulon-IV HBX microtiter plates (Thermo Labsystems, Franklin, MA) were
coated overnight at 4°C with rPA, rLF, or the anti-PA and anti-LF human MAbs
at a concentration of 1 g/ml in 0.2 M carbonate buffer (pH 7.4). Each plate
included a standard curve comprising doubling dilutions of purified mouse
anti-PA IgG (provided by S. Park, BioPort Corp., Lansing, MI) or nonspecific
human IgG (Sigma, St. Louis, MO) at concentrations ranging from 1,000 to 1.95
ng/ml. Plates were blocked with 5% (wt/vol) nonfat milk in PBS plus 0.1%
(vol/vol) Tween 20 (pH 7.4) (PBST) for 1 h at 37°C and washed three times with
PBST. Serum samples were serially diluted twofold in PBST and captured on the
antigen-coated wells for 1 h at 37°C. Following washing, bound antibodies were
detected using species-specific horseradish peroxidase-conjugated antibody. The
secondary antibody was incubated in the wells for 1 h at 37°C. Plates were
developed with the SureBlue Reserve substrate (Kirkegaard and Perry Labora-
tories, Gaithersburg, MD). The reaction was stopped by addition of 1 N HCl, and
the absorbance at 450 nm was read with a standard ELISA plate reader. Optical
density values in the linear portion and range of the standard curve were used to
interpolate the IgG concentrations (g/ml) in the samples. Results were ex-
pressed as geometric mean concentrations and geometric standard deviations
(SD). All statistical analyses were conducted in Excel (Microsoft, Redmond,
WA) using t tests assuming normality, and a P value of 0.05 was considered
significant.
The abilities of the murine anti-PA and anti-LF antibodies in the terminal
bleed sera to neutralize LeTx were measured in J774A.1 mouse macrophage
cytotoxicity assays as described previously (15, 40). These assays were conducted
using 66.8 ng/ml of rPA and 53.5 ng/ml of rLF to achieve more than 95% cell lysis
at a fixed cell density of 3  104 cells/well as determined by toxin potency testing.
Prior to analysis, human MAbs were absorbed out of the terminal bleed sera
using BioMag particles covalently attached to Fc-specific goat anti-human IgG
(Bangs Laboratories, Fishers, IN). Briefly, 250 g of BioMag particles was
washed four times with PBS and suspended in 270 l (final volume) of PBS. The
washed beads were mixed with 30 l of terminal bleed serum and incubated for
30 min at room temperature with agitation (table top vortex mixer at the lowest
setting). This step was repeated two more times with 250 g of fresh beads each
time. Reacted beads were magnetically removed using a Dynal neodymium
iron-boron magnet (Invitrogen, Carlsbad, CA). At the end of the third incuba-
tion the BioMag particles were separated from the serum by centrifugation and
by using the magnet. This procedure was found to have no adverse effect on the
mouse IgG titer in the sample (data not shown). Absorbed serum was stored at
4°C until it was analyzed.
Pharmacokinetic analysis of human MAb in mice. The pharmacokinetics of
the anti-PA and anti-LF antibodies in mice were determined using the ELISA
protocol described above. This assay measured the residual human IgG present
in the mice using rPA and rLF as the target antigens and an horseradish perox-
idase-conjugated rabbit anti-human IgG antibody (Jackson ImmunoResearch
Laboratories, West Grove, PA) to detect the bound human antibodies. The IgG
concentration data were modeled with Data Fit 8.1 (Oakdale Engineering, Oak-
dale, PA) using a nonlinear exponential curve defined by the following equation:
t1/2  t2  t1  	ln(2)/ln	Ct1/Ct2

, where t1 and t2 are times 1 and 2,
respectively, Ct1 and Ct2 are the human MAb concentrations at t1 and t2, respec-
tively, and t1/2 is the half-life.
FIG. 1. Toxin neutralization by IQNPA and IQNLF. The abilities of both antibodies to neutralize a given amount of toxin were evaluated using
the TNA assay (‚ and ). In order to determine if combining IQNPA and IQNLF had a positive or negative effect on neutralization, the two
MAbs were mixed in various ratios prior to use in the assay (Œ and ). The results are expressed as the effective concentration of antibody that
protected 50% of the cells in the assay (EC50).
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RESULTS
Isolation of human MAbs. Electrofusion hybridoma tech-
nology generated 250 stable hybridoma cell lines expressing
PA-specific MAbs, five of which (2%) were able to neutralize
anthrax toxin activity (data not shown). Ten stable LF-specific
hybridoma cell lines were obtained, two of which (20%) pro-
duced anti-LF MAbs capable of neutralizing anthrax toxin
(data not shown). From these pools two MAbs, an anti-PA
IgG1 MAb designated IQNPA and an anti-LF IgG1 MAb
designated IQNLF, were selected for further study based on
their performance in the preliminary cytotoxicity assays.
Toxin neutralization by IQNPA and IQNLF. In the TNA
assay reported here, MAb IQNLF (EC50, 0.1 nM) was 3-fold
more effective than IQNPA (EC50, 0.3 nM) and IQNPA and
IQNLF were approximately 4- and 11-fold more effective than
the human polyclonal reference standard AVR801 (EC50, 1.1
nM), respectively. Individually, increasing the concentrations
of IQNPA and IQNLF in the TNA assay had a minimal effect
on the EC50 (Fig. 1). This is indicative of the independent
neutralizing activities of the two antibodies. Increasing the
concentration of IQNLF in the presence of a constant IQNPA
concentration or increasing the concentration of IQNPA in the
presence of a constant IQNLF concentration resulted in over-
all neutralization per total protein (nM) that was intermediate
between that of the more potent IQNLF antibody and that of
the IQNPA antibody. The parallel shifts of the ED50s for these
combinations (data not shown) suggested that the neutraliza-
tion activities of IQNPA and IQNLF have independent roles in
toxin neutralization. Had the slopes been steeper, this would
have indicated a synergistic effect. The EC50s demonstrate that
there is a linear one-to-one relationship between the toxin
neutralization capacities of IQNPA and IQNLF when they are
combined (Fig. 1), confirming that their neutralizing activities
are not synergistic but additive.
Domain mapping of toxin-neutralizing antibodies. Six GST
fusions of the individual PA domains and combinations of
these domains were produced and tested for IQNPA binding/
recognition. Each fusion was named based on the PA do-
main(s) that it contains. IQNPA strongly recognized GSTI-IV,
GSTIII-IV, and GSTIV but not GSTI, GSTI-II, or GSTI-III,
indicating that the neutralizing epitope is within domain IV
(Table 1). This binding recognition of domain IV was con-
firmed in a denatured and native protein Western blot analysis
(data not shown).
The four recombinant domains of LF plus a fifth construct
encompassing domains II to IV were probed with IQNLF via
native and denatured protein Western blot analysis. Domain I
was consistently recognized in both blots by IQNLF, while
domains II, III, IV, and II to IV were not recognized, demon-
strating that the neutralizing epitope is located within domain
I (Fig. 2).
In vivo protective efficacy against B. anthracis spore chal-
lenge. The ability of a single 180-g dose of either IQNPA or
IQNLF to confer passive protection in A/J mice against 24 LD50s
of B. anthracis Sterne spores was determined. Antibody adminis-
tered 2.5 h prior to i.p. challenge protected 100% of the mice over
the course of the study with no overt clinical signs of illness (Fig.
3). The mice in the untreated control group had a mean time to
death (MTD) of 87  27 h (MTD  SD), and B. anthracis was
cultured from the heart tissue of these mice at the time of death.
The protected mice were subjected to a second lethal spore
challenge (41 LD50s) 20 days later. Once again, these animals
survived until the end of the experiment on day 34 without
overt illness (Fig. 3). Necropsy and tissue cultures from these
mice failed to detect the presence of B. anthracis. In contrast,
the second set of untreated controls had a MTD  SD of 69 
18 h and were bacteremic at the time of death.
Stimulation of mouse anti-PA and anti-LF antibody re-
sponses. Analysis of the collected serum samples indicated that
mice protected by the MAbs mounted an antitoxin antibody
response following the initial infection that increased signifi-
FIG. 2. rLF domain recognition by IQNLF. (A and B) SDS-denatured and native Western blots probed with IQNLF. (C) Silver-stained
SDS-denaturing gel showing the approximate size of each domain. The gels were loaded with markers (left and right lanes) and the same
concentration (50 ng) of each of the following constructs: full-length rLF (lane 1), LF domain I (lane 2), LF domain II (lane 3), LF domain III
(lane 4), LF domain IV (lane 5), and LF domains II to IV (lane 6).
TABLE 1. Domain mapping of IQNPA by ELISA endpoint titer
Fusion(s)a IQNPA endpoint titer
GSTI ..................................................................................1:100
GSTI-II..............................................................................1:100
GSTI-III ............................................................................1:100
GSTI-IV ............................................................................ 1:128,000b
GSTIII-IV ......................................................................... 1:256,000b
GSTIV ............................................................................... 1:128,000b
a Equimolar concentrations of fusions were used based on the requirement for
6.02  1011 mol/ml (equivalent to 5 m/ml rPA).
b Endpoint titers greater than 1:12,800 were defined as positive reactions and
indicated that IQNPA bound within the domain.
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cantly (P  0.05) after the second challenge (Fig. 4). These
murine responses were specific to the antigen recognized by
the human MAb that the mice received prior to challenge. The
animals receiving IQNPA produced significantly more anti-PA
IgG than anti-LF IgG by days 17 and 27 (P  0.05), while the
mice that received IQNLF produced significantly more anti-LF
IgG than anti-PA IgG by days 17, 27, and 35 (P  0.001) (Fig.
4). ELISAs confirmed that the murine antibody concentrations
were not due to the exogenous human IgG in the sera cross-
reacting with the secondary anti-mouse IgG used in the assays.
Mouse anti-IQNPA and anti-IQNLF IgG responses also in-
creased from a background geometric mean titer (GMT) of 0.7
g/ml prior to treatment to 12.9  2.4 and 8.7  1.6 g/ml,
respectively, by day 34 (data not shown).
The toxin-neutralizing capacity of the endogenous mouse
IgG response produced after the second challenge was evalu-
ated. Terminal bleed sera from the mice receiving IQNPA had
a geometric mean ED50 of 100  2 (n  6), while the geomet-
ric mean ED50 of the terminal bleed sera from mice receiving
IQNLF was 213  3 (n  7). This neutralization activity had a
FIG. 3. Protection of mice from an i.p. anthrax spore challenge by prechallenge injection of IQNPA and IQNLF. Mice were inoculated i.p. with
180 g of either IQNPA (n 10) or IQNLF (n 10) 2.5 h prior to an i.p. spore challenge consisting of 24 LD50s. The MTD SD for the untreated
controls was 87  27 h. Twenty days later surviving mice were rechallenged with 41 LD50s. In this second challenge the MTD  SD for the controls
was 69  18 h.
FIG. 4. Mouse specific anti-toxin IgG titers after B. anthracis Sterne strain spore challenge. Anti-PA and anti-LF IgG titers were measured in
five sample bleeds taken during the course of the study. Solid symbols (Œ and F) indicate GMTs obtained for mice treated with IQNPA, while
open symbols (‚ and E) indicate GMTs obtained for mice treated with IQNLF. Mice were challenged on days 0 and 20, as indicated by the vertical
dashed lines. Mice produced a modest amount of anti-toxin IgG 10 days after the first challenge, which increased following the second challenge
on day 20. Mice treated with IQNPA produced a greater anti-PA IgG response than anti-LF IgG response, while the converse was true for mice
receiving IQNLF.
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 o
n
 February 24, 2014 by Cardiff Univ
http://iai.asm
.org/
D
ow
nloaded from
 
positive correlation with the murine anti-PA and anti-LF
ELISA titers (R2  0.58 and R2  0.51, respectively), but it
could not be attributed to nonspecific serum protection, since
pooled naı¨ve serum from the same mice prior to treatment
failed to protect macrophages (data not shown). Nor can neu-
tralization be attributed to the presence of residual IQNPA or
IQNLF, since serum samples that had detectable concentra-
tions of these antibodies in ELISA after absorption were ex-
cluded from the analysis.
Clearance of human MAbs. Both antibodies were retained
in the bloodstream of all mice; however, IQNPA persisted at a
higher level than IQNLF throughout the course of the 34-day
study (Fig. 5). IQNPA was detected in the mice at a GMT of
85.8  1.4 g/ml on day 10 (the first posttreatment/challenge
bleed), and the level decreased 77.5% to 19.3  1.5 g/ml by
day 34. IQNLF was initially detected at a level of 73.6  1.3
g/ml, and the level decreased 91.3% to 6.4  1.8 g/ml by the
end of the study. The half-life of IQNPA in mice is 11.2 days,
while that of IQNLF is 6.8 days.
DISCUSSION
The currently recommended postexposure therapeutic treat-
ment for anthrax is a combination of antibiotics (ciprofloxacin or
doxycycline), licensed human vaccine (AVA), and, in severe
cases, intravenously administered preformed human polyclonal
anthrax immunoglobulin (AIGIV) derived from immunized do-
nors (9; http://www2.niaid.nih.gov/Biodefense/Research/products
.htm#a1). The advantages of using AIGIV are that it provides
instant protection, is likely to be effective during mid- to ad-
vanced-stage disease, is equally effective against antibiotic-resis-
tant strains, results in minimal adverse reactions, has a prolonged
serum half-life, and targets multiple epitopes, making it difficult to
subvert its efficacy (52; L. Price, A. J. Vogler, S. James, and P.
Keim, presented at the 4th International Conference on Anthrax,
10 to 13 June, 2001, Annapolis, MD). Despite these advantages
AIGIV does suffer from the need to maintain and constantly
renew stocks of antibodies with sufficiently high toxin neutraliza-
tion potency from an immunologically diverse population of do-
nors. An alternative approach would be to develop protective
human MAbs with neutralizing specificity for PA and LF that
could be used individually or in combination and can be manu-
factured on a large scale (http://www2.niaid.nih.gov/Biodefense
/Research/products.htm#a1).
Here two fully human MAbs, IQNPA and IQNLF, with the
ability to neutralize separate components of the anthrax LeTx
and to passively protect mice upon spore challenge are de-
scribed. Most importantly, these antibodies did not interfere
with the development of endogenous anti-PA and anti-LF im-
mune responses.
Both antibodies were specific for their cognate antigens and
independently had a greater capacity to neutralize LeTx than
the reference polyclonal serum. Isolation of hybridomas pro-
ducing potent toxin-neutralizing antibodies is indicative of
germ line antibodies that have matured through genetic re-
combination, somatic hypermutation, and extensive selection.
This structural plasticity plays a critical role in the ability of the
immune system to adapt and produce highly specific, high-
affinity neutralizing antibodies (62). When combined in vitro,
IQNPA and IQNLF were found to have a composite effect on
LeTx neutralization intermediate between their individual ef-
fects, suggesting that they function independent of each other
and noncompetitively by neutralizing unrelated processes dur-
ing LeTx intoxication. Importantly, this MAb combination did
not have a deleterious effect on LeTx neutralization.
In order to plausibly explain the ability of IQNPA and
IQNLF to neutralize LeTx without interfering with each other,
their antigen binding domains were identified. The specific
recognition of PA domain IV by IQNPA suggests that this
MAb impedes the interaction of PA with the host cell. PA
domain IV has been implicated in binding to cell surface re-
ceptors (5, 47, 57); therefore, it is reasonable to propose that
IQNPA probably interferes with the attachment of PA to
capillary morphogenesis protein 2 and/or tumor endothelial
marker 8. Several LF-neutralizing antibodies have also been
identified in other studies (25, 63), one of which binds domain
FIG. 5. Clearance of IQNPA and IQNLF in vivo. The levels of IQNPA and IQNLF asymptotically decreased by 77.5 and 91.3%, respectively,
over the course of the 34-day study. The half-life (t1/2) of each antibody was calculated using the formula: t1/2  t2  t1  ln2/ln	Ct1/Ct2
,
where t1 and t2 are times 1 and 2, respectively, and Ct1 and Ct2 are the MAb titers at t1 and t2, respectively. Using this equation, IQNPA had a
half-life of 11.2 days, while IQNLF had a half-life of 6.8 days.
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III and exerts its protective effect by a mechanism that is not
clear yet (25). In contrast, the binding of IQNLF to LF domain
I indicates that it may obstruct the formation of the LeTx
complex by disrupting or preventing the interaction of LF with
proteolytically active PA63, which occurs between amino acids
in PA domains I and II and LF domain I (8, 24). The fact that
IQNPA and IQNLF bind to protein domains that are involved
in separate yet related processes during intoxication logically
explains why the MAb combination did not have a negative
effect on LeTx neutralization.
Prophylactic administration of 180 g of IQNPA or IQNLF
as a single, stand-alone treatment resulted in 100% survival. To
our knowledge, IQNLF is the first fully human LF-specific
MAb capable of conferring complete protection against such a
challenge. Analysis of the postmortem heart swabs revealed
that antibody-treated animals not only were protected during
both challenges but were able to clear the infecting organism.
The observation that both antibodies persisted in the mice
over the course of the study is indicative of their IgG1 subclass,
which is reported to have an in vivo half-life of 7 to 21 days (34,
50, 51). This is a desirable quality for a prophylactic or thera-
peutic antibody considering that B. anthracis spores can persist
in the lungs and the environment long after a biological attack
(11, 12). Although the calculated half-lives of IQNPA and
IQNLF were 11.2 and 6.8 days, respectively, we have been able
to demonstrate that 45 g of IQNPA and 22 g of IQNLF are
able to fully protect mice against a lethal spore challenge
(unpublished data). In the present study, these concentrations
were detected in mouse serum on day 21 for IQNPA and on
day 17 for IQNLF. Based on these observations, it is quite
possible that survival after the second challenge was due to
both the residual human MAb in circulation and the endoge-
nous murine anti-LeTx antibodies produced after challenge.
Analysis of the endogenous murine antibody response prior
to the second challenge and at the end of the study revealed
that in addition to the human MAbs the serum also contained
mouse anti-PA- and anti-LF-specific polyclonal IgGs. The con-
centrations of these endogenous IgGs were substantially
boosted following the second challenge and included antibod-
ies with toxin-neutralizing activity. This was not unexpected
and is consistent with previous studies using human or human-
ized PA-specific MAbs (33, 37). Although the endogenous IgG
concentrations reported here were below previously identified
serological correlates of protection (27, 38, 42) and the ED50s
and IgG concentrations are weakly correlated, their contribu-
tion to protection cannot be ruled out. It is quite possible that
the titers would have become more robust if there had been
more time between the two challenges.
Interestingly, the magnitudes of the endogenous PA- and
LF-specific antibody responses were dependent on which hu-
man antibody the mice received prior to challenge. Mice given
IQNPA generated a significantly higher IgG response to PA
than to LF (P  0.05), while mice inoculated with IQNLF
generated a significantly higher IgG response to LF than to PA
(P  0.001). These findings support the hypothesis that the
toxin-neutralizing capacities of IQNPA and IQNLF not only
allow the development of a protective endogenous antibody
response against PA and LF but also may in fact stimulate this
humoral response.
One possible explanation for this immunostimulatory effect
is the formation of antigen-antibody immune complexes and
their subsequent binding to Fc receptors on macrophages and
natural killer cells. This process would specifically enhance PA
and LF antigen uptake and presentation on major histocom-
patibility complex molecules to stimulate T- and B-cell expan-
sion and the subsequent production of endogenous murine
polyclonal antibodies to PA and LF, as was observed. During
application in humans (or higher-order mammals) IQNPA and
IQNLF may also fix complement, a feature of IgG1; however,
since the A/J mouse is C5 deficient, the full effect of comple-
ment cannot be discussed in terms of the present study (http:
//jaxmice.jax.org/strain/000646.html).
Recent work examining the potential role of IQNPA and IQNLF
in antibody-dependent cell-mediated cytotoxicity (ADCC) indicates
that these MAbs can also function opsonically (Alan Cross, personal
communication) to clear vegetative bacilli. This may explain the ab-
sence of bacteremia in the surviving mice. As a natural consequence
of ADCC a variety of anthrax antigens are released that aid in the
establishment of a robust polyclonal antibody response to the vege-
tative bacilli.
Due to the observed phenomena it is reasonable to infer that
IQNPA and IQNLF not only passively protected the mice but
primed and immunized them as a result of the antibody treat-
ment in combination with the challenge organism. The ability
of therapeutic antibodies to confer protection while at the
same time enabling or even stimulating an individual to gen-
erate his or her own protective immune response is an ex-
tremely desirable property. This observation may have impli-
cations for enhancing responses to the existing licensed
anthrax vaccine when it is used as a postexposure therapy.
We concluded, based on the data presented here, that pas-
sive protection and immunostimulation against B. anthracis by
IQNPA and IQNLF occur through toxin neutralization to in-
hibit separate processes of anthrax intoxication. This may be
due to inhibition of PA binding to the host cell surface and
inhibition of LeTx formation. Once PA and LF are bound by
IQNPA and IQNLF, it is likely that they will be delivered to
antigen-presenting cells for antigen processing and presenta-
tion, thus initiating the observed B-cell responses. T-cell re-
sponses may also have been elicited, but this was not evaluated.
The clearance of the circulating vegetative bacilli by ADCC
may have also contributed to protection. Evaluation of these
mechanisms during IQNPA- and IQNLF-mediated passive
protection is ongoing.
While the use of one of these MAbs is likely to be effective
during passive protection, there are concerns about the delib-
erate circumvention of epitope binding sites within PA or LF
resulting in a protein whose biological activity is no longer
inhibited by a previously protective antibody. Indeed, the fea-
sibility of just such an event has been reported for PA (16). As
a consequence, the NIAID “Expert Consultation on Monoclo-
nal Antibodies for Anthrax” has recommended that research-
ers consider developing a cocktail of MAbs which target dif-
ferent regions of the anthrax LeTx (http://www2.niaid.nih.gov
/Biodefense/Research/products.htm#a1). To this end, a
treatment composed of both IQNPA and IQNLF would be
valuable. This treatment would broaden the spectrum of pro-
tection by ensuring that toxin formation and activity are
blocked at two independent levels, namely, cellular attachment
and LF binding, with two distinct antibodies.
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We propose that administration of a single dose of antibody
comprising a cocktail of human MAbs targeting PA and LF
would provide immediate and broad-spectrum protection to
naı¨ve populations while facilitating the establishment of an
endogenous protective immune response in exposed individu-
als. The use of multiple antibodies specific to different toxins
should be of particular value in the event of exposure to novel
anthrax-causing strains in which PA has been altered by nature
or genetic engineering to abolish epitopes incorporated in the
currently licensed vaccines.
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